The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Influence of Statin Medications on Prostate-specific Antigen Levels
Abstract
BACKGROUND: Recent data suggest that statin use may be associated with a reduced risk of advanced prostate cancer. However, the influence of statins on prostate-specific antigen (PSA) levels and what effect this could potentially have on prostate cancer diagnosis are unknown. METHODS: We conducted a longitudinal study of 1214 men who were prescribed a statin between 1990 and 2006 at the Durham Veterans Affairs Medical Center who were free of prostate cancer, had not undergone prostate surgery or taken medications known to alter androgen levels and who had at least one PSA value within 2 years before and at least one PSA value within 1 year after starting a statin. The change in PSA from before to after statin treatment was analyzed as a continuous variable using the Wilcoxon signed rank test. The association between change in PSA and change in cholesterol parameters (low-density lipoprotein [LDL], high-density lipoprotein [HDL], and total cholesterol) was analyzed using multivariate linear regression. All statistical tests were two-sided. RESULTS: Mean (SD) age when starting statins was 60.3 (8.3) years; median prestatin PSA concentration was 0.9 (1.9) ng/mL; and mean prestatin LDL cholesterol concentration was 144 (34) mg/dL. After starting a statin, the median LDL decline was 27.5%, and the median PSA decline was 4.1% (P < .001, for both comparisons). Changes in PSA concentration were strongly associated with statin dose and changes in LDL levels. For every 10% decrease in LDL after starting a statin, PSA levels declined by 1.64 (95 % confidence interval [CI] = 0.64% to 2.65%, p = .001). Among men most likely to be under consideration for prostate biopsy (prestatin PSA levels > or =2.5 ng/mL, n = 188), those with >41% declines in LDL (highest quartile) after starting a statin experienced a 17.4% (95% CI = 10.0% to 24.9%) decline in serum PSA. CONCLUSIONS: PSA levels declined by a statistically significant extent after initiation of statin treatment. The reduction was most pronounced among men with the largest LDL declines and those with PSA levels that would make them candidates for prostate biopsy. By lowering PSA levels, statins may complicate cancer detection, although further studies are needed to quantify the clinical significance of this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567
Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey
Hall, S. A., Page, S. T., Travison, T. G., Montgomery, R. B., Link, C. L., & McKinlay, J. B. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0306 · Cited by 69
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Statin use and cancer risk: a comprehensive review
Boudreau, D. M., Yu, O., & Johnson, J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003662620 · Cited by 274
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription
Toepfer, N., Childress, C., Parikh, A., Rukstalis, D., & Yang, W. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.8.15978 · Cited by 67
Metadata
- Authors
- Hamilton, R. J., Goldberg, K. C., Platz, E. A., & Freedland, S. J.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-11-05
- Volume
- 100
- Issue
- 21
- Pages
- 1511-1518
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2131793954
- Cited by
- 162
- References
- 3
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Influence of Statin Medications on Prostate-specific Antigen Levels. https://app.cochat.ai/papers/10.1093/jnci/djn362
- The paper
- Hamilton, R. J., Goldberg, K. C., Platz, E. A., & Freedland, S. J. (2008). The Influence of Statin Medications on Prostate-specific Antigen Levels. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djn362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.